{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:03:38Z","timestamp":1784765018443,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cld.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:37:09Z","timestamp":1780313829000},"page":"761-774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoglobulin G4\u2013Related Sclerosing Cholangitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Kareem","family":"Khalaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Causada","family":"Calo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2026.04.004_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2020.100074","article-title":"IgG4-related disease: changing epidemiology and new thoughts on a multisystem disease","volume":"4","author":"Floreani","year":"2021","journal-title":"J Transl Autoimmun"},{"issue":"6","key":"10.1016\/j.cld.2026.04.004_bib2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jhep.2023.08.005","article-title":"IgG4-related cholangitis \u2013 a mimicker of fibrosing and malignant cholangiopathies","volume":"79","author":"Kersten","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00535-011-0465-z","article-title":"Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification","volume":"47","author":"Nakazawa","year":"2012","journal-title":"J Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2026.04.004_bib4","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/ajg.2014.223","article-title":"Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort","volume":"109","author":"Huggett","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-011-0508-6","article-title":"A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jhbp.596","article-title":"Clinical practice guidelines for IgG4-related sclerosing cholangitis","volume":"26","author":"Kamisawa","year":"2019","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.cld.2026.04.004_bib7","article-title":"IgG4-related digestive diseases: diagnosis and treatment","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cld.2026.04.004_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1959832","article-title":"IgG4-Related sclerosing cholangitis: rarely diagnosed, but not a rare disease","volume":"2021","author":"Drazilova","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.004_bib9","article-title":"Current and future advances in practice: IgG4-related disease","volume":"8","author":"Wallace","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"11","key":"10.1016\/j.cld.2026.04.004_bib10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/intimm\/dxu074","article-title":"IgG4-related disease and its pathogenesis-cross-talk between innate and acquired immunity","volume":"26","author":"Umehara","year":"2014","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/BOR.0000000000000558","article-title":"New insights into IgG4-related disease: emerging new CD4+ T-cell subsets","volume":"31","author":"Kamekura","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.004_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cld.1087","article-title":"Hepatic manifestations of immunoglobulin G4-Related disease","volume":"18","author":"Sharzehi","year":"2021","journal-title":"Clin Liver Dis"},{"issue":"23","key":"10.1016\/j.cld.2026.04.004_bib13","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.3748\/wjg.v26.i23.3126","article-title":"Review of primary sclerosing cholangitis with increased IgG4 levels","volume":"26","author":"Manganis","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2026.04.004_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s00535-018-1484-9","article-title":"Clinical guidelines for primary sclerosing cholangitis 2017","volume":"53","author":"Isayama","year":"2018","journal-title":"J Gastroenterol"},{"issue":"43","key":"10.1016\/j.cld.2026.04.004_bib15","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.3748\/wjg.v19.i43.7661","article-title":"Diagnosis of IgG4-related sclerosing cholangitis","volume":"19","author":"Nakazawa","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.004_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00535-016-1163-7","article-title":"IgG4-related sclerosing cholangitis: all we need to know","volume":"51","author":"Zen","year":"2016","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.mayocpiqo.2021.03.005","article-title":"Diagnosing biliary strictures: distinguishing IgG4-Related sclerosing cholangitis from cholangiocarcinoma and primary sclerosing cholangitis","volume":"5","author":"Hori","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"8","key":"10.1016\/j.cld.2026.04.004_bib18","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2026.04.004_bib19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.gie.2015.04.030","article-title":"Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review","volume":"82","author":"Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"10.1016\/j.cld.2026.04.004_bib20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cgh.2019.07.035","article-title":"Optimizing outcomes of single-operator cholangioscopy-guided biopsies based on a randomized trial","volume":"18","author":"Bang","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.004_bib21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/diagnostics13061023","article-title":"Endoscopic ultrasound in the diagnosis of extrahepatic cholangiocarcinoma: what do we know in 2023?","volume":"13","author":"Orzan","year":"2023","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00535-012-0744-3","article-title":"Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system","volume":"48","author":"Okazaki","year":"2013","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.004_bib23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1177\/2050640620934911","article-title":"European guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations","volume":"8","author":"L\u00f6hr","year":"2020","journal-title":"United Eur Gastroenterol J"},{"issue":"10","key":"10.1016\/j.cld.2026.04.004_bib24","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1093\/rheumatology\/kev244","article-title":"Methotrexate for maintenance of remission in IgG4-related disease","volume":"54","author":"Della-Torre","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.cld.2026.04.004_bib25","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1038\/ctg.2017.17","article-title":"Azathioprine maintenance therapy to prevent relapses in autoimmune pancreatitis","volume":"8","author":"de Pretis","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"10.1016\/j.cld.2026.04.004_bib26","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","article-title":"Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial","volume":"5","author":"Perugino","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5009\/gnl210116","article-title":"Classification and diagnostic criteria for IgG4-Related sclerosing cholangitis","volume":"16","author":"Naitoh","year":"2022","journal-title":"Gut Liver"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/nu15030576","article-title":"Prognostic significance of severe vitamin D deficiency in patients with primary sclerosing cholangitis","volume":"15","author":"Ebadi","year":"2023","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.cld.2026.04.004_bib29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.cgh.2016.12.038","article-title":"Clinical features, response to treatment, and outcomes of IgG4-Related sclerosing cholangitis","volume":"15","author":"Tanaka","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib30","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","article-title":"Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy","volume":"134","author":"Ghazale","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2026.04.004_bib31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.semarthrit.2020.01.010","article-title":"Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: a randomized clinical trial","volume":"50","author":"Wang","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/key227","article-title":"Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial","volume":"58","author":"Yunyun","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib33","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1038\/s41598-017-06520-5","article-title":"Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids","volume":"7","author":"Yunyun","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40674-020-00147-w","article-title":"Therapeutic options in IgG4-Related disease","volume":"6","author":"Fern\u00e1ndez-Codina","year":"2020","journal-title":"Current Treatment Options in Rheumatology"},{"issue":"4","key":"10.1016\/j.cld.2026.04.004_bib35","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/rheumatology\/kez380","article-title":"Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis","volume":"59","author":"Omar","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cld.2026.04.004_bib36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3389\/fmed.2020.00253","article-title":"Comparison of the effects of cyclophosphamide and mycophenolate Mofetil treatment against Immunoglobulin G4-Related disease: a retrospective cohort Study","volume":"7","author":"Luo","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.cld.2026.04.004_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/gastro\/goaf032","article-title":"Management of IgG4-related cholangitis: diagnosis, therapy, and long-term surveillance","volume":"13","author":"Herta","year":"2025","journal-title":"Gastroenterology Report"},{"issue":"1 Suppl","key":"10.1016\/j.cld.2026.04.004_bib38","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2026.04.004_bib39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/MCG.0000000000001984","article-title":"A review of IgG4-related sclerosing cholangitis (IgG4-SC)","volume":"58","author":"Khoury","year":"2024","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5114\/ceh.2018.78126","article-title":"A good response to steroid therapy in IgG4-related sclerosing cholangitis: a case report","volume":"4","author":"Zhang","year":"2018","journal-title":"Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cld.642","article-title":"IgG4-related sclerosing cholangitis","volume":"10","author":"Culver","year":"2017","journal-title":"Clinical Liver Disease"},{"issue":"6","key":"10.1016\/j.cld.2026.04.004_bib42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.cld.2026.04.004_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2169\/internalmedicine.50.4321","article-title":"Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease","volume":"50","author":"Tabata","year":"2011","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib44","first-page":"186","article-title":"Risk factors of relapse following glucocorticoid tapering in IgG4-related disease","volume":"36 Suppl 112","author":"Sasaki","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.cld.2026.04.004_bib45","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/rheumatology\/kez669","article-title":"Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort","volume":"59","author":"Liu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.cld.2026.04.004_bib46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/joim.12942","article-title":"Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study","volume":"286","author":"Peng","year":"2019","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.cld.2026.04.004_bib47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MPA.0000000000001007","article-title":"Relative rise of serum IgG4 levels after steroid therapy for autoimmune pancreatitis predicts the likelihood of relapse","volume":"47","author":"Suzuki","year":"2018","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.cld.2026.04.004_bib48","first-page":"491","article-title":"Autoimmune pancreatitis and IgG4-related systemic diseases","volume":"3","author":"Zhang","year":"2010","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib49","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jhep.2014.04.016","article-title":"IgG4 cholangiopathy: current concept, diagnosis, and pathogenesis","volume":"61","author":"Okazaki","year":"2014","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2026.04.004_bib50","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-Related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2026.04.004_bib51","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2665-9913(21)00359-3","article-title":"Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study","volume":"4","author":"Matza","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13075-022-02792-z","article-title":"Clinical and pathological predictors of relapse in IgG4-related disease","volume":"24","author":"Zongfei","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s42358-024-00374-y","article-title":"IgG4-related disease-rare but you should not forget it","volume":"64","author":"Pinheiro","year":"2024","journal-title":"Adv Rheumatol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.004_bib54","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.jhep.2023.09.026","article-title":"Primary sclerosing cholangitis with high immunoglobulin-G4","volume":"80","author":"Malakar","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.004_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282852","article-title":"Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease","volume":"18","author":"Choi","year":"2023","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.cld.2026.04.004_bib56","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/modpathol.2009.94","article-title":"IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material","volume":"22","author":"Deshpande","year":"2009","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.cld.2026.04.004_bib57","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006400","article-title":"Poor response of initial steroid therapy for IgG4-related sclerosing cholangitis with multiple organs affected","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"8","key":"10.1016\/j.cld.2026.04.004_bib58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4251\/wjgo.v5.i8.181","article-title":"Cholangiocarcinoma developed in a patient with IgG4-related disease","volume":"5","author":"Douhara","year":"2013","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000513029","article-title":"IgG4-Related sclerosing cholangitis mimicking cholangiocarcinoma","volume":"14","author":"Minh Thong","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.004_bib60","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00261-019-01944-1","article-title":"Differentiating IgG4-related sclerosing cholangiopathy from cholangiocarcinoma using CT and MRI: experience from a tertiary referring center","volume":"44","author":"Swensson","year":"2019","journal-title":"Abdom Radiol (NY)"},{"issue":"4","key":"10.1016\/j.cld.2026.04.004_bib61","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.gastro.2018.06.082","article-title":"Gastrointestinal and extra-intestinal manifestations of IgG4-Related disease","volume":"155","author":"Miyabe","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2026.04.004_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152253","article-title":"Assessment of patient-reported symptoms and distress in IgG4-related disease (IgG4-RD): development, clinical validation, and content validation of the IgG4-RD symptom severity index","volume":"63","author":"Wallace","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.cld.2026.04.004_bib63","article-title":"Long-term usage of oral glucocorticoids leading to adrenal insufficiency: a comprehensive review of the literature","volume":"15","author":"Monge Chac\u00f3n","year":"2023","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.cld.2026.04.004_bib64","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/1744666X.2017.1354698","article-title":"Diagnostic and treatment workup for IgG4-related disease","volume":"13","author":"Abraham","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.cld.2026.04.004_bib65","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.41140","article-title":"Disease severity linked to increase in autoantibody diversity in IgG4-Related disease","volume":"72","author":"Liu","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cld.2026.04.004_bib66","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9399.1","article-title":"Recent advances in understanding and managing IgG4-related disease","volume":"6","author":"Wolfson","year":"2017","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.cld.2026.04.004_bib67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4068\/cmj.2021.57.1.44","article-title":"Role of endoscopic procedures in the diagnosis of IgG4-Related pancreatobiliary disease","volume":"57","author":"Jung","year":"2021","journal-title":"Chonnam Med J"},{"issue":"1124","key":"10.1016\/j.cld.2026.04.004_bib68","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210105","article-title":"(18)F-FDG PET\/CT manifestations of IgG4-related disease","volume":"94","author":"Tang","year":"2021","journal-title":"Br J Radiol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.004_bib69","article-title":"Artificial intelligence and radiomics in cholangiocarcinoma: a comprehensive review","volume":"15","author":"Zerunian","year":"2025","journal-title":"Diagnostics (Basel)"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:36:18Z","timestamp":1784763378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1089326126000383"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin G4\u2013Related Sclerosing Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}